bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated September 23, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Sep 30, 2024 to Jun 30, 2025
    • Start date: Oct 1, 2023 to May 20, 2024
    • Study completion date: Sep 30, 2025 to Dec 30, 2025
    • Site details revised
  4. Lead sponsor: Zhou Qunfang to Sun Yat-sen Universityv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with intermediate-advanced huge hepatocellular carcinoma.
Trial Details
NCT Number NCT06061276
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab, Lenvatinib
Related terms Carcinoma, Hepatocellular, Liver Diseases
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov